Future Science OA (Feb 2021)

Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases

  • Shing Yi Pan,
  • Yvonne Cashinn Chia,
  • Hui Rong Yee,
  • Angelina Ying Fang Cheng,
  • Clarice Evey Anjum,
  • Yenny Kenisi,
  • Mike KS Chan,
  • Michelle BF Wong

DOI
https://doi.org/10.2144/fsoa-2020-0142
Journal volume & issue
Vol. 7, no. 2

Abstract

Read online

The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.